GoHealth, Inc. (GOCO): debt financing — GoHealth secures $115M superpriority term loan, amends credit agreement, and appoints three new directors

GoHealth, Inc.

Secured $115M superpriority term loan facility with $80M in new-money term loans and $35M in roll-up loans.
Amended existing credit agreement to waive principal payments through 2026 and reset financial covenants.
Issued 4,766,219 shares of Class A common stock to lenders as consideration for the amendment.
Appointed Timothy R. Pohl, Alan J. Carr, and William L. Transier to the board; three directors resigned.
Reported Q2 2025 financial results and announced transformation committee for strategic alternatives.

item 1.01 item 2.02 item 2.03 item 3.02 item 5.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.98

GoHealth, Inc. incurred term loan of $115,000,000 with Blue Torch Finance, LLC at Term SOFR plus 5.50% or Alternate Base Rate plus 4.50% maturing August 5, 2029.

Instrument: term loan
Principal: $115,000,000
Counterparty: Blue Torch Finance, LLC
Rate: Term SOFR plus 5.50% or Alternate Base Rate plus 4.50%
Maturity: August 5, 2029
Event: incurrence

Exact text from the filing

the Borrower entered into a Superpriority Senior Secured Credit Agreement (the “Priming Credit Agreement”), with Holdings, the lenders party thereto, and Blue Torch Finance, LLC, as administrative agent and as collateral agent. The Priming Credit Agreement governs a senior secured super priority term loan facility in an aggregate principal amount of $115.0 million (the “Priming Facility”)

View on SEC.gov

Browse all debt financings →

GoHealth, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-25-038578

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.